Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Table 1.

Drug side effects resources.

More »

Table 1 Expand

Table 2.

Drug indication resources.

More »

Table 2 Expand

Figure 1.

Construction of drug network using side effects.

More »

Figure 1 Expand

Table 3.

The 2×2 contingency table of drug A and indication i.

More »

Table 3 Expand

Figure 2.

The trends of covered drugs and drug-drug pairs that share the same terms in the MeSH hierarchy.

More »

Figure 2 Expand

Table 4.

Top 10 ATC therapeutic categories with NDCG@5≥0.7.

More »

Table 4 Expand

Table 5.

Prediction performance of the 1234 drugs in different indication range (number of network drugs approved for an indication).

More »

Table 5 Expand

Table 6.

Predicted results with evidence supported at an EASE score≤10−5.

More »

Table 6 Expand

Figure 3.

Sub-network of Dynastat.

Each node represents a drug. Drugs approved for pain management are marked in yellow. Drugs approved for rheumatoid arthritis therapy are marked in purple.

More »

Figure 3 Expand

Figure 4.

Sub-network of Tasmar.

Each node represents a drug. Drugs approved for the treatment of Parkinson's disease are marked in orange. Drugs approved for rheumatoid arthritis therapy are marked in blue.

More »

Figure 4 Expand

Figure 5.

Sub-network of Adamon.

Each node represents a drug. Drugs approved for the treatment of Parkinson 's disease are marked in orange. Drugs approved for pain treatment are marked in blue.

More »

Figure 5 Expand

Table 7.

The similarity of 98 SIDER drugs in test sample set with the drugs in the network.

More »

Table 7 Expand

Table 8.

Predicted drug-indication pairs of SIDER drugs.

More »

Table 8 Expand